Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials

DOI10.1111/j.1541-0420.2009.01302.xzbMath1192.62224OpenAlexW2050950840WikidataQ33945668 ScholiaQ33945668MaRDI QIDQ3576931

Hoang Q. Nguyen, Nadine Houede, Xavier Paoletti, Peter F. Thall, Andrew Kramar

Publication date: 3 August 2010

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc2893272

zbMATH Keywords

utilityclinical trialadaptive designBayesian designcombination dose finding

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Medical applications (general) (92C50)

Related Items (8)

Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data ⋮ Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion ⋮ A Bayesian Phase I/II Trial Design for Immunotherapy ⋮ Bayesian models and decision algorithms for complex early phase clinical trials ⋮ Simple benchmark for complex dose finding studies ⋮ Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies ⋮ A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes ⋮ Rejoinder

Cites Work

• Unnamed Item
• Unnamed Item
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Dose-Finding Designs for HIV Studies
• Dose-Finding with Two Agents in Phase I Oncology Trials
• Design and Analysis of Phase I Clinical Trials
• A New Dose‐Finding Design for Bivariate Outcomes
• Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
• On two families of transformations to additivity for binary response data
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial

This page was built for publication: Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials